Friday, August 7, 2026 - KFF Health News
• On Thursday, August 6, 2026, the FDA granted accelerated approval to vusolimogene oderparepvec (Tudriqev), also known as RP1, for use in combination with nivolumab (Opdivo). • This genetically modified oncolytic viral therapy is specifically indicated for adults with unresectable advanced cutaneous melanoma who have seen disease progression after anti-PD-1-based therapy. • Karim Mikhail, acting director of the FDA's Center for Biologics Evaluation and Research, stated that the approval provides more patients with a "fighting chance" against advanced cancer.
kffhealthnews.org












